Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma

Published:2018-08-09 Issue:23 Volume:24 Page:5990-6000
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Shi Ruoshi,Li Ming,Raghavan Vibha,Tam Shirley,Cabanero Michael,Pham Nhu-An,Shepherd Frances A.,Moghal Nadeem,Tsao Ming-Sound

Funder

Canadian Institute of Health Research Foundation grant

CIHR

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression and prognostic value of cell‐cycle‐associated genes in lung squamous cell carcinoma;The Journal of Gene Medicine;2024-08-22

2. Clinical and pathological predictors of engraftment for patient-derived xenografts in lung adenocarcinoma;Lung Cancer;2024-08

3. Nanomaterials Enhance Pyroptosis-Based Tumor Immunotherapy;International Journal of Nanomedicine;2024-06

4. Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example;Molecular Biomedicine;2024-04-15

5. CDK4/6 inhibitors in lung cancer: current practice and future directions;European Respiratory Review;2024-01-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP